232 related articles for article (PubMed ID: 15840681)
1. Limitations of C2 monitoring in renal transplant recipients.
Einecke G; Schütz M; Mai I; Fritsche L; Giessing M; Glander P; Neumayer HH; Budde K
Nephrol Dial Transplant; 2005 Jul; 20(7):1463-70. PubMed ID: 15840681
[TBL] [Abstract][Full Text] [Related]
2. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
[TBL] [Abstract][Full Text] [Related]
3. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
[TBL] [Abstract][Full Text] [Related]
4. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
Jaksch P; Kocher A; Neuhauser P; Sarahrudi K; Seweryn J; Wisser W; Klepetko W
J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
[TBL] [Abstract][Full Text] [Related]
5. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporin exposure correlates with 1 year graft function and histological damage in renal transplanted patients.
di Paolo S; Teutonico A; Stallone G; Infante B; Schena A; Grandaliano G; Battaglia M; Ditonno P; Schena PF
Nephrol Dial Transplant; 2004 Aug; 19(8):2107-12. PubMed ID: 15187199
[TBL] [Abstract][Full Text] [Related]
7. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
[TBL] [Abstract][Full Text] [Related]
8. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Hübler M; Abd El Rahman MY; Miera O; Ewert P; Weng Y; Wei H; Krüdewagen B; Hetzer R; Berger F
J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and C2 cyclosporin monitoring in maintenance renal transplant recipients: 1 year follow-up study.
Marcén R; Villafruela JJ; Pascual J; Teruel JL; Ocaña J; Tenorio MT; Burgos FJ; Ortuño J
Nephrol Dial Transplant; 2005 Apr; 20(4):803-10. PubMed ID: 15687111
[TBL] [Abstract][Full Text] [Related]
10. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.
Carstens J
Scand J Urol Nephrol; 2008; 42(3):286-92. PubMed ID: 18432535
[TBL] [Abstract][Full Text] [Related]
11. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study.
Kyllönen LE; Salmela KT
Transplantation; 2006 Apr; 81(7):1010-5. PubMed ID: 16612277
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study.
Iversen M; Nilsson F; Sipponen J; Eiskjaer H; Mared L; Bergan S; Nyström U; Fagertun HE; Solbu D; Simonsen S
J Heart Lung Transplant; 2009 Sep; 28(9):919-26. PubMed ID: 19716045
[TBL] [Abstract][Full Text] [Related]
13. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
Akhlaghi F; Gonzalez L; Trull AK
J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0.
Loichot C; Bentue-Ferrer D; Bernard N; Bonardet A; Boulieu R; Kergueris MF; Paintaud G; Peytavin G; Simon N; Marquet P;
Fundam Clin Pharmacol; 2006 Feb; 20(1):91-6. PubMed ID: 16448399
[TBL] [Abstract][Full Text] [Related]
15. Outcome of microemulsion cyclosporine C2 concentration monitoring in kidney transplantation.
Praditpornsilpa K; Avihingsanon Y; Nivatvong S; Kansanabuch T; Eiam-Ong S; Tiranathanagul K; Chusil S; Tungsanga K
Clin Transplant; 2005 Jun; 19(3):335-9. PubMed ID: 15877794
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation.
Barnard JB; Thekkudan J; Richardson S; Bittar MN; Martyszczuck R; Hasan J; Khasati N; Keevil B; Yonan N
J Heart Lung Transplant; 2006 May; 25(5):564-8. PubMed ID: 16678036
[TBL] [Abstract][Full Text] [Related]
17. Decision support tool to individualize cyclosporine dose in stable, long-term heart transplant recipients receiving metabolic inhibitors: overcoming limitations of cyclosporine C2 monitoring.
Ray JE; Keogh AM; McLachlan AJ
J Heart Lung Transplant; 2006 Oct; 25(10):1223-9. PubMed ID: 17045935
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes.
Delgado DH; Rao V; Hamel J; Miriuka S; Cusimano RJ; Ross HJ
J Heart Lung Transplant; 2005 Sep; 24(9):1343-6. PubMed ID: 16143255
[TBL] [Abstract][Full Text] [Related]
19. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.
Bunnag S; Vareesangthip K; Ong-ajyooth L
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S228-34. PubMed ID: 17044476
[TBL] [Abstract][Full Text] [Related]
20. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
